After Hours
After-hours and pre-market trading may carry slightly higher risks than regular market hours. As issuers often announce important financial information outside regular trading hours, extended-hours trading may result in wider spreads for a particular security. That is because extended-hours trading may result in lower liquidity and higher volatility.
Stocks Info
BBIO belongs to the Healthcare sector of the NASDAQ while operating in the Biotechnology industry. The current market capitalization of BridgeBio Pharma Inc is $6.68B. A total of 1.19 million shares were traded on the day, compared to an average of 3.02M shares.
In the most recent transaction, Kumar Neil sold 75,000 shares of BBIO for 36.87 per share on Mar 25 ’25. After the transaction, the Chief Executive Officer now owns 4,948,447 company shares. In a previous transaction on Mar 06 ’25, Valantine Hannah sold 12,875 shares at 32.58 per share. BBIO shares that Director owns now total 1,764.
Among the insiders who sold shares, KKR Genetic Disorder L.P. disposed of 6,000,000 shares on Mar 05 ’25 at a per-share price of $32.96. This resulted in the 10% Owner holding 19,260,971 shares of BBIO after the transaction. In another insider transaction, HANNAH A VALANTINE bought 12,875 shares at $32.58 per share on Mar 06 ’25.
While price targets are rarely accurate, they tend to exert some kind of influence from time to time and are often taken into account by investors. In terms of 52-week highs and lows, BBIO has a high of $39.47 and a low of $21.62.
Balance Sheet Annually/Quarterly
An organization’s balance sheet depicts the assets and liabilities it has, as well as the amount of equity invested. Investors can measure a company’s prospects by calculating its financial ratios using this information. BBIO’s latest balance sheet shows that the firm has $836.66M in Cash & Short Term Investments as of fiscal 2021. There were $1.73B in debt and $135.07M in liabilities at the time. Its Book Value Per Share was -$7.72, while its Total Shareholder’s Equity was -$865.58M.
Analysts Opinion
There is a slight risk associated with trading before and after the market open. Due to lower liquidity and higher volatility, extended-hours trading may result in wider spreads on particular security due to the release of critical financial information after regular trading hours. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for BBIO is Buy with a score of 4.71.
